Acumen Pharmaceuticals, Inc. Common Stock · XNAS · 131 sessions on record
$2.22▼ −0.02 · −1.1%from $2.25 the session before · Sep 30, 2026 close · end of day
Open
$2.25
High
$2.45
Low
$2.10
Day's range
$0.3516% of the previous close
VWAP
$2.28close −2.7% from it
Volume, shares
1.48M3.26× the 20-session average
Traded, $
$3.4M
Trades
7.4K200 shares per trade
Previous close
$2.25−0.02 to the close
Market cap
$160.5Mat the close of Sep 30
Day range34% of the way up
$2.10$2.45
52-week range11% of the way up
$2.08 May 19$3.34 Aug 21
−34% from the high · +6.7% from the low
Options
No listed options on ABOS
Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it
consolidated · latest filed Aug 12, 2026 · SEC filings
Profit −$32.7M in the Jun 2026 quarter, consolidated.
Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of ABOS on the consolidated basis with the market's move on the first session after each filing
Quarter
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
Market on the day
Jun 2026filed Aug 12
—
—
−$32.7M
—
-0.45
▲ +1.6%S&P 500 +0.7% · +0.9 pp
Mar 2026filed May 12
—
—
−$20.7M
—
-0.33
▲ +0.4%S&P 500 +0.6% · −0.2 pp
Dec 2025filed Mar 26
—
—
−$25.1M
—
-0.40
▼ −11.4%S&P 500 −1.7% · −9.7 pp
Sep 2025filed Nov 12
—
—
−$26.5M
—
-0.44
—not reached
Jun 2025filed Aug 12
—
—
−$41.0M
—
-0.68
▲ +1.6%S&P 500 +0.7% · +0.9 pp
Mar 2025filed May 12
—
—
−$28.8M
—
-0.48
▲ +0.4%S&P 500 +0.6% · −0.2 pp
Dec 2024filed Mar 27
—
—
−$37.2M
—
-0.62
—not reached
Sep 2024filed Nov 12
—
—
−$29.8M
—
-0.50
—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of ABOS on the consolidated basis, summed from the quarters filed
Year
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
FY25to Dec 2025
—
—
−$121.3M
—
-2.00
FY24to Dec 2024
—
—
−$102.3M
—
-1.71
FY23to Dec 2023
—
—
−$52.4M
—
-1.08
FY22to Dec 2022
—
—
−$42.9M
—
-1.06
FY21to Dec 2021
—
—
−$100.6M
—
-5.02
Fundamentals
consolidated · filings to Jun 2026 · close $2.22 on Sep 30
2.8 times book value, market cap $160.5M.
Valuation
Market cap
$160.5Mon Sep 30
Price to earnings
—
Trailing EPS
$-1.62diluted · consolidated · four quarters to Jun 2026
Price to book
2.8consolidated · balance sheet to Jun 2026
Book value a share
$0.79consolidated · balance sheet to Jun 2026
Debt to equity
0.21borrowings over equity · consolidated · balance sheet to Jun 2026
Return on equity
-120%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
—
Shares outstanding
72.3Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$105.0Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
Shareholding
SEC Forms 3, 4 and 5
No open-market insider buying or selling in the last 90 days.
Insider tradesSEC Forms 3, 4 and 5 · the latest 10
ABOS insider trades
Insider
Trade
Shares
Price
Held after
Porter DerrellDirector
exercised · Jun 15, 2026
6,460
$1.07
54,760
Porter DerrellDirector
sold · Jun 15, 2026
6,460
$2.35
48,300
Porter DerrellDirector
sold · Jun 17, 2026
13,040
$2.33
35,500
Porter DerrellDirector
exercised · Jun 17, 2026
13,040
$1.07
48,540
Porter DerrellDirector
sold · Jun 16, 2026
12,800
$2.33
35,500
Fountain Nathan BDirector
sold · Jun 9, 2026
6,400
$2.23
48,150
RA Capital Nexus Fund II, L.P.Director
granted · Jun 3, 2026
35,500
$0.00
48,300
Stoppel LauraDirector
granted · Jun 3, 2026
35,500
$0.00
48,300
Golumbeski GeorgeDirector
granted · Jun 3, 2026
35,500
$0.00
35,500
Ives Jeffrey L.Director
granted · Jun 3, 2026
35,500
$0.00
48,300
Corporate actions
exchange records
No corporate action on record for ABOS yet.
Price history
131 sessions on record · to Sep 30 · end of day
ABOS is −24.0% over 20 sessions against the S&P 500's +0.1%, 34% below its 52-week high, realised volatility 81% annualised.
Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
Window
From $
ABOS %
S&P 500 %
Difference pp
120 sessionssince Apr 9
$2.51
▼ −12%
▲ +12%
−24
60 sessionssince Jul 7
$2.57
▼ −14%
▲ +2.0%
−16
20 sessionssince Sep 1
$2.92
▼ −24%
▲ +0.11%
−24
5 sessionssince Sep 23
$2.31
▼ −3.7%
▼ −0.67%
−3.0
1 sessionsince Sep 29
$2.24
▼ −1.1%
▼ −0.21%
−0.90
Averages of the closeclose against each average
5-session average
$2.25close −1.3% from it
20-session average
$2.67close −17% from it
50-session average
$2.61close −15% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.209.1% of the close
Average day's range, 20
$0.167.4% of the close
Volume against 20 sessions
3.26×1.48M vs 520K average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
81%≈ ±5.1% a session · moved more than that on 4 of 20
Realised volatility, 60
72%≈ ±4.6% a session · moved more than that on 10 of 60
Beta to S&P 500, 60
1.23moved with S&P 500 on 33 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
9 up · 11 downof 20
Last 60 sessions
30 up · 29 downof 59
Best session, 250
▲ +17%Jun 29
Worst session, 250
▼ −13%Sep 23
Short-sale volume
25 sessions · to Sep 30, 2026
Short sales were 26% of reported volume on Sep 30, 2026, against 56% over the last 25 sessions.
Last 10 sessionsshare of the day's reported volume
OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.